机译:Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Int Breast Canc Ctr IBCC||Med Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIR;
Med Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIR||Hosp Prof Doutor Fernando Fonseca EPE;
Hosp Ruber IntHosp Univ Virgen del RocioHosp Clin Univ ValenciaUniv CordobaInt Breast Canc Ctr IBCC||Hosp Univ DexeusIOB Inst Oncol||IOB Inst OncolHosp del MarMed Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIR||Hosp Prof Doutor Fernando Fonseca EPE||Fdn Inst Valenciano OncolUniv Hosp Ramon y CajalHosp LuzHosp Univ DexeusMed Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIR||Hosp Arnau Vilanova||Univ Catolica ValenciaMed Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIRInt Breast Canc Ctr IBCC||Med Scientia Innovat Res MEDSIR||Med Scientia Innovat Res MEDSIR||Univ Europea Madrid;
advanced breast cancer; brain metastases; HER2-positive; T-DXd; trastuzumab deruxtecan;